Treatment with caspase-1 inhibitor diminishes kidney disease in MRL-Faslpr mice and delays systemic illness
Objectives To investigate the therapeutic potential of caspase-1 inhibition in systemic lupus erythematosus (SLE) and lupus nephritis (LN) using the MRL-Faslpr mouse model.Methods Female Murphy Roths large (MRL)-Faslpr mice were treated with a caspase-1 inhibitor (pralnacase) or sham treatment from...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2025-12-01
|
| سلاسل: | RMD Open |
| الوصول للمادة أونلاين: | https://rmdopen.bmj.com/content/11/4/e006194.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|